NCT02877225View on ClinicalTrials.gov

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

November 11, 2016

Study Completion Date

November 11, 2016

Conditions
Healthy
Interventions
DRUG

Ibrutinib

Ibrutinib (test treatment) 140 milligram (mg), tablet.

DRUG

IMBRUVICA

IMBRUVICA (reference treatment), 140-mg capsule

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02877225 - Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule | Biotech Hunter | Biotech Hunter